Тем временем... (вместо послесловия)

Согласно последней статье в Nature Biotechnology [62], началось несколько клинических испытаний по перепрофилированию лекарств в целях лечения COVID-19. Один из подходов заключается в перепрофилировании известных противовирусных препаратов, в основном из арсенала анти-ВИЧ-терапии. Имеются наблюдения, которые указывают на возможность перекрестного эффекта против коронавируса. Второй перспективный подход касается воздействия на организм человека, чтобы уменьшить «цитокиновый шторм», вызываемый иммунным ответом на вирус [63].

Разработка вакцин

В настоящее время около 70 компаний и научных коллективов по всему миру ведут разработку вакцин, список исследований опубликован ВОЗ. Три вакцины находятся на стадии клинических испытаний. А среди вакцин на стадии доклинической разработки — «предложения» на любой вкус. Много ДНК-вакцин и вакцин на основе рекомбинатных белков; при создании одной из них вирусные белки даже будут экспрессироваться в растениях. Есть несколько разработок с безыгольным впрыском в кожу и даже в виде капель или спрея в нос. Так что есть надежда, что у нас не только скоро будет вакцина, но прививка будет еще и безболезненной! Здорово, правда?

Исходный вариант этой статьи опубликован в журнале «Природа» №3 за 2020 г. [64] .

Литература

1. Хроника распространения SARS-CoV-2;
2. 2019-nCoV: очередной коронованный убийца?;
3. COVID-19: отвечаем на вопросы;
4. COVID-19: что мы знаем и чего не знаем;
5. Roujian Lu, Xiang Zhao, Juan Li, Peihua Niu, Bo Yang, et. al.. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 395, 565-574;
6. Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Hu Y. et al. (2020). Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. bioRxiv;
7. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. (2020). The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 5, 536-544;
8. McIntosh K. and Perlmanin S. Coronaviruses, including severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). In: Mandell, Douglas, and Bennett's principles and practice of infectious diseases (eighth edition) / ed. by Bennett J.E., Dolin R., Blaser M.J. Elsevier Inc., 2014. P. 1928–1936;
9. Carter J.B. and Saunders V.A. Virology: principles and applications. Chichester, 2007;
10. Кулагина М.Г. Коронавирусная инфекция // Инфекционные болезни: национальное руководство / Н.Д. Ющук, Ю.Я. Венгеров. М., 2018. С. 759–768;
11. . (2012). Nidovirales. Virus Taxonomy. 784-794;
12. Vineet D Menachery, Boyd L Yount, Kari Debbink, Sudhakar Agnihothram, Lisa E Gralinski, et. al.. (2015). A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 21, 1508-1513;
13. Zhengli Shi, Zhihong Hu. (2008). A review of studies on animal reservoirs of the SARS coronavirus. Virus Research. 133, 74-87;
14. David Cyranoski. (2020). Mystery deepens over animal source of coronavirus. Nature. 579, 18-19;
15. Anthony R. Fehr, Stanley Perlman. (2015). Coronaviruses: An Overview of Their Replication and Pathogenesis. Coronaviruses. 1-23;
16. Markus Hoffmann, Hannah Kleine-Weber, Simon Schroeder, Nadine Krüger, Tanja Herrler, et. al.. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell;
17. Canrong Wu, Yang Liu, Yueying Yang, Peng Zhang, Wu Zhong, et. al.. (2020). Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B;
18. C M Chu. (2004). Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 59, 252-256;
19. Ying-Hui Jin, , for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM), Lin Cai, Zhen-Shun Cheng, Hong Cheng, et. al.. (2020). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military Med Res. 7;
20. Поиск лекарственных мишеней;
21. Zhenming Jin, Xiaoyu Du, Yechun Xu, Yongqiang Deng, Meiqin Liu, et. al.. (2020). Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature;
22. Ting-Wai Lee, Maia M. Cherney, Jie Liu, Karen Ellis James, James C. Powers, et. al.. (2007). Crystal Structures Reveal an Induced-fit Binding of a Substrate-like Aza-peptide Epoxide to SARS Coronavirus Main Peptidase. Journal of Molecular Biology. 366, 916-932;
23. Xu Z., Peng C., Shi Y., Zhu Zh., Mu K., Wang X., Zhu W. (2020). Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. bioRxiv;
24. Silke Stertz, Mike Reichelt, Martin Spiegel, Thomas Kuri, Luis Martínez-Sobrido, et. al.. (2007). The intracellular sites of early replication and budding of SARS-coronavirus. Virology. 361, 304-315;
25. Eric F. Pettersen, Thomas D. Goddard, Conrad C. Huang, Gregory S. Couch, Daniel M. Greenblatt, et. al.. (2004). UCSF Chimera?A visualization system for exploratory research and analysis. J. Comput. Chem.. 25, 1605-1612;
26. Franck Touret, Xavier de Lamballerie. (2020). Of chloroquine and COVID-19. Antiviral Research. 177, 104762;
27. Виртуальные тропы реальных лекарств;
28. 12 методов в картинках: «сухая» биология;
29. Драг-дизайн: как в современном мире создаются новые лекарства;
30. Григорий Никифорович: «От оргазма до бессмертия. Записки драг-дизайнера». Рецензия;
31. Торжество компьютерных методов: предсказание строения белков;
32. Молекулярная динамика биомолекул. Часть I. История полувековой давности;
33. Liu X. and Wang X.J. (2020). Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines. bioRxiv;
34. Li Y., Zhang J., Wang N., Li H., Shi Y., Guo G. et al. (2020). Therapeutic drugs targeting 2019-nCoV main protease by high-throughput creening. bioRxiv;
35. Eric F. Pettersen, Thomas D. Goddard, Conrad C. Huang, Gregory S. Couch, Daniel M. Greenblatt, et. al.. (2004). UCSF Chimera?A visualization system for exploratory research and analysis. J. Comput. Chem.. 25, 1605-1612;
36. Рулетка для спектроскописта;
37. Lili Chen, Chunshan Gui, Xiaomin Luo, Qingang Yang, Stephan Günther, et. al.. (2005). Cinanserin Is an Inhibitor of the 3C-Like Proteinase of Severe Acute Respiratory Syndrome Coronavirus and Strongly Reduces Virus Replication In Vitro. JVI. 79, 7095-7103;
38. Edward Kim, Zach Jensen, Alexander van Grootel, Kevin Huang, Matthew Staib, et. al.. (2020). Inorganic Materials Synthesis Planning with Literature-Trained Neural Networks. J. Chem. Inf. Model.. 60, 1194-1201;
39. Andrew W. Senior, Richard Evans, John Jumper, James Kirkpatrick, Laurent Sifre, et. al.. (2020). Improved protein structure prediction using potentials from deep learning. Nature. 577, 706-710;
40. Alex Zhavoronkov, Yan A. Ivanenkov, Alex Aliper, Mark S. Veselov, Vladimir A. Aladinskiy, et. al.. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 37, 1038-1040;
41. Zhavoronkov A., Aladinskiy V., Zhebrak A., Zagribelnyy B., Terentiev V., Bezrukov D.S. et al. (2020). Potential COVID-2019 3C-like protease inhibitors designed using generative deep learning approaches. chemRxiv;
42. Peter Richardson, Ivan Griffin, Catherine Tucker, Dan Smith, Olly Oechsle, et. al.. (2020). Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet. 395, e30-e31;
43. Lemonick S. (2020). Two groups use artificial intelligence to find compounds that could fight the novel coronavirus. Chemical and Engineering News. 98, 6;
44. Gao K., Nguyen D.D., Wang R., Wei G.W. (2020). Machine intelligence design of 2019-nCoV drugs. bioRxiv;
45. Peter Ertl, Ansgar Schuffenhauer. (2009). Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J Cheminform. 1;
46. Nguyen D.D., Gao K., Chen J. (2020). Potentially highly potent drugs for 2019-nCoV. bioRxiv;
47. Anh-Tien Ton, Francesco Gentile, Michael Hsing, Fuqiang Ban, Artem Cherkasov. (2020). Rapid Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease by Deep Docking of 1.3 Billion Compounds. Mol. Inf.;
48. Gentile F., Agrawal V., Hsing M., Ban F., Norinder U., Gleave M.E., Cherkasov A. (2019). Deep docking — a deep learning approach for virtual screening of big chemical datasets. bioRxiv;
49. Beck B.R., Shin B., Choi Y., Choi Y., Park S., Kang K. (2020). Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model. bioRxiv;
50. Kevin D. Raney, Suresh D. Sharma, Ibrahim M. Moustafa, Craig E. Cameron. (2010). Hepatitis C Virus Non-structural Protein 3 (HCV NS3): A Multifunctional Antiviral Target. J. Biol. Chem.. 285, 22725-22731;
51. Bzówka M., Mitusińska K., Raczyńska A., Samol A., Tuszyński J.A., Góra A. (2020). Structural and evolutionary analysis Indicate that the SARS-CoV-2 Mpro is an inconvenient target for small-molecule inhibitors design. bioRxiv;
52. Bin Cao, Yeming Wang, Danning Wen, Wen Liu, Jingli Wang, et. al.. (2020). A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med;
53. Huang A., Tang X., Wu H., Zhang J., Wang W., Wang Z. et al. (2020). Virtual screening and molecular dynamics on blockage of key drug targets as treatment for COVID-19 caused by SARS-CoV-2. Preprints;
54. Contini A. (2020). Virtual screening of an FDA approved drugs database on two COVID-19 coronavirus proteins. ResearchGate;
55. Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S. et al. (2020). Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor. bioRxiv;
56. Daniel Wrapp, Nianshuang Wang, Kizzmekia S. Corbett, Jory A. Goldsmith, Ching-Lin Hsieh, et. al.. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 367, 1260-1263;
57. Alexandra C. Walls, Young-Jun Park, M. Alejandra Tortorici, Abigail Wall, Andrew T. McGuire, David Veesler. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell;
58. Yan R., Zhang Y., Guo Y., Xia L., Zhou Q. (2020). Structural basis for the recognition of the 2019-nCoV by human ACE2. bioRxiv;
59. Smith M. and Smith J.C. (2020). Repurposing therapeutics for COVID-19: supercomputer-based docking to the SARS-CoV-2 viral spike protein and viral spike protein-human ACE2 interface. chemRxiv;
60. Zhang L. and Zhou R. (2020). Binding mechanism of remdesivir to SARS-CoV-2 RNA dependent RNA polymerase. Preprints;
61. Travis K. Warren, Robert Jordan, Michael K. Lo, Adrian S. Ray, Richard L. Mackman, et. al.. (2016). Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 531, 381-385;
62. Charlotte Harrison. (2020). Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 38, 379-381;
63. Puja Mehta, Daniel F McAuley, Michael Brown, Emilie Sanchez, Rachel S Tattersall, Jessica J Manson. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 395, 1033-1034;
64. Маджидов Т.И. и Куракин Г.Ф. (2020). Компьютерные технологии против коронавируса: первые результаты. «Природа». 3, 3–15;
65. Alexander E. Gorbalenya, Luis Enjuanes, John Ziebuhr, Eric J. Snijder. (2006). Nidovirales: Evolving the largest RNA virus genome. Virus Research. 117, 17-37;
66. Peter Forster, Lucy Forster, Colin Renfrew, Michael Forster. (2020). Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci USA. 202004999.

 

---

Дата добавления: 2022-01-22; просмотров: 23; Мы поможем в написании вашей работы!

Поделиться с друзьями:

---

---

Мы поможем в написании ваших работ!